Bronchiolitis News and Research

RSS

Needle-free vaccine shows promise against RSV in children

Researchers at the University of Saskatchewan are closing in on a needle-free vaccine for respiratory syncytial virus (RSV), a major cause of respiratory illness in children under two years of age.

30 Mar 2012

Extremely contagious RSV virus can lead to serious illness in young children

Respiratory Syncytial Virus (RSV) is a common virus that infects the lungs and breathing passage ways. Though it may only produce minor cold symptoms in adults, it can lead to serious illness in young children and those with compromised immune systems.

17 Mar 2012

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

Pfizer Inc. announced today that data from a Phase 3 study of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.

12 Mar 2012

Pfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in adults over 50

Pfizer Inc. issued the following statement in response to today's discussion by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) regarding the use of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine)in adults 50 years of age and older.

23 Feb 2012

PERC-led study recognized as one of Canada's top achievements in health research

You could call it paying it forward. A trip to the Emergency Department (ED) is every parent's worst nightmare. But what if the information documented as a result of your child's visit could help a child with similar symptoms a few provinces away? Terry Klassen and his research team of leading pediatric emergency physicians at Pediatric Emergency Research of Canada (PERC) have done just that and the impact of their research is today recognized as one of the Top Canadian Achievements in Health Research in 2011.

24 Jan 2012

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults.

31 Dec 2011

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Pfizer Inc. today announced it has entered into a second supply agreement which will broaden and extend the duration of the Company's commitment to help protect millions of infants and young children in the developing world from pneumococcal disease - the leading cause of vaccine-preventable death in young children.

17 Dec 2011

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed patient enrollment in its Phase IIb study with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection.

29 Nov 2011

Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA

Pfizer Inc. announced today that additional data from several clinical studies of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America, which is being held Oct. 20-23, 2011, in Boston, Mass.

22 Oct 2011

RSV medication from specialty pharmacies increases likelihood of children receiving recommended doses

Children given an injectable medication to help prevent severe respiratory illness had a 17.6 percent higher likelihood of receiving the American Academy of Pediatrics (AAP) recommended doses when they were administered through a specialty pharmacy rather than a traditional pharmacy, according to a new study released today by pharmacy benefit manager Prime Therapeutics (Prime).

21 Oct 2011

NIH-funded study to evaluate rescue medications for victims of toxic gases

National Jewish Health researchers have received nearly $13 million from the National Institutes of Health to evaluate potential rescue medications for victims of terrorist attacks, wartime use of toxic gases, and/or inhalation disasters. The gases of greatest interest in these studies will be 'mustard gas' (sulfur mustard) and chlorine gas.

14 Oct 2011

MicroDose initiates MDT-637 Phase 1 trial in respiratory syncytial virus

MicroDose Therapeutx, Inc. today announced that the first human subject has been dosed in a Phase 1 clinical trial of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus.

28 Sep 2011

Hasbro Children's Hospital joins Pediatric Emergency Care Applied Research Network

The emergency medicine department at Hasbro Children's Hospital has received a grant that will support its participation in the Pediatric Emergency Care Applied Research Network (PECARN). This is the nation's first federally funded pediatric research network focused on the prevention and management of acute illnesses and injuries in children of all ages.

8 Sep 2011

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

NanoBio Corporation announced today that data from recent animal studies of its NanoStat-based intranasal respiratory syncytial virus (RSV) vaccine have been published in PLoS One, an international peer-reviewed online publication.

25 Aug 2011

NIH, NanoBio sign licensing agreement to develop vaccine against RSV infections

NanoBio Corporation today announced a licensing agreement with the National Institutes of Health (NIH) that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.

4 Aug 2011

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

Pfizer Inc today announced that the U.S. Food and Drug Administration (FDA) has issued a 90-day extension to the action date for the Company's supplemental Biologics License Application (sBLA) for use of Prevnar 13, in adults aged 50 and older.

30 Jul 2011

Breathing problems trouble U.S. soldiers returning from Iraq and Afghanistan, speculation about inhaled toxins

According to a new study some U.S. soldiers returning from Iraq and Afghanistan are suffering unexplained breathing problems that may be related to exposure to unknown toxins.

21 Jul 2011

Exposure to household tobacco smoke increases risk of bronchiolitis in infants

A study by the University of Liverpool has found that babies admitted to hospital with bronchiolitis from a household where a parent smokes are twice as likely to need oxygen therapy and five times as likely to need mechanical ventilation as babies whose parents do not smoke.

21 Jul 2011

New paper provides unique review on respiratory disorders in the Middle East

Lung diseases in the Middle East range from the centuries-old pulmonary tuberculosis (TB) to modern manifestations caused by chemical warfare. A new paper now available in Respirology, a journal of the Asian Pacific Society of Respirology, provides pulmonologists and patients with the first comprehensive review of respiratory illnesses specific to the Persian Gulf region, and the challenges in treating them.

14 Jul 2011

Serious RSV infections may occur in previously healthy infants and children

For most parents, respiratory syncytial virus (RSV) isn't a familiar term. But it's a common cause of serious respiratory infections with a major impact on the health of infants and young children worldwide, according to a special CDC Review Article in the June issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

16 Jun 2011